Press Releases

LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascular (CV) events such as stroke Hospitalization costs for patients following a major bleeding event associated with oral anticoagulation use averages $39,000 per event Tecarfarin, with its novel metabolic pathway, potentially may offer an alternative to warfarin in this vulnerable population PONTE VEDRA, Fla. – Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing novel therapeutics for patients

PONTE VEDRA, Fla. – Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced that members of its executive leadership team will be attending and participating in the upcoming BIO International Convention 2025, taking place June 16-19, 2025 in Boston. Cadrenal executives will participate in one-on-one meetings with investors and potential partners to provide key updates on the Company’s strategic direction and clinical development of its lead asset,

PONTE VEDRA, Fla. – Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced manufacturing and supply chain milestones for its lead drug candidate, tecarfarin, a novel oral vitamin K antagonist (VKA) anticoagulant that is designed to address unmet needs in anticoagulation therapy. Cadrenal completed the technical transfer and manufacturing of its tecarfarin drug substance in accordance with current good manufacturing practices (cGMP) earlier this year at a

Leadership appointment strengthens strategic and development capabilities FDA Type D Meeting provides additional guidance for advancing the clinical development of tecarfarin Collaboration Agreement with Abbott (NYSE: ABT) validates the need for new anticoagulation options PONTE VEDRA, Fla. – Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today reported its financial results for the first quarter ended March 31, 2025, and provided an update on the strategic focus of

PONTE VEDRA, Fla. – Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced that Chairman and CEO Quang X. Pham will present at the inaugural Centri Capital Conference, to be held at Nasdaq in New York City on April 22, 2025. Mr. Pham will deliver a company overview and provide updates on the development of tecarfarin, Cadrenal’s lead asset, addressing unmet needs in